In vivo activation of gene transcription via oestrogen response elements by a raloxifene analogue

Journal of Endocrinology

Volumn 203, Issue 3, 2009, Pages 349-356

  Engdahl, Cecilia ^a   Jochems, Caroline ^a   Gustafsson, Jan Åke ^b   Van Der Saag, Paul T ^c   Carlsten, Hans ^a   Lagerquist, Marie K ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HUBRECHT INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

6 HYDROXY 2 (4 HYDROXYPHENYL) 3 [4 [2 (1 PYRROLIDINYL)ETHOXY]BENZOYL]BENZO[B]THIOPHENE; ESTRADIOL BENZOATE; ESTROGEN; LUCIFERASE; RALOXIFENE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE; BONE DENSITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME ACTIVITY; ESTROGEN RESPONSIVE ELEMENT; GENE ACTIVATION; GENETIC TRANSCRIPTION; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPORTER GENE; SINGLE DRUG DOSE; THYMUS; THYMUS ATROPHY; UTERUS; UTERUS WEIGHT; WEIGHT GAIN;

ANIMALS; BONE DENSITY; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; FEMUR; LUCIFERASES; MICE; MICE, INBRED CBA; MICE, TRANSGENIC; ORGAN SIZE; PYRROLIDINES; RALOXIFENE; RECEPTORS, ESTROGEN; RESPONSE ELEMENTS; THIOPHENES; THYMUS GLAND; TRANSCRIPTION, GENETIC; UTERUS;

EID: 71949107502     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-09-0012     Document Type: Article

References (37)

1. Ashby J, Odum J & Foster JR 1997 Activity of raloxifene in immature and ovariectomized rat uterotrophic assays. Regulatory Toxicology and Pharmacology 25 226-231. (Pubitemid 27308536)
2. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC, Cullinan GJ, Bendele R, Kauffman RF, Bensch WR et al. 1994 Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. Journal of Clinical Investigation 93 63-69. (Pubitemid 24030821)
3. Bryant HU, Glasebrook AL, Yang NN & Sato M 1996 A pharmacological review of raloxifene. Journal of Bone and Mineral Metabolism 14 1-9.
4. Bryant HU, Glasebrook AL, Yang NN & Sato M 1999 An estrogen receptor basis for raloxifene action in bone. Journal of Steroid Biochemistry and Molecular Biology 69 37-44. (Pubitemid 29305524)
5. Buelke-Sam J, Cohen IR, Wierda D, Griffey KI, Fisher LF & Francis PC 1998 The selective estrogen receptor modulator, raloxifene: a segment II/III delivery study in rats. Reproductive Toxicology 12 271-288. (Pubitemid 29110890)
6. Cheskis BJ, Karathanasis S & Lyttle CR 1997 Estrogen receptor ligands modulate its interaction with DNA. Journal of Biological Chemistry 272 11384-11391. (Pubitemid 27184143)
7. Cheung J, Mak YT, Papaioannou S, Evans BA, Fogelman I & Hampson G 2003 Interleukin-6 (IL-6), IL-1, receptor activator of nuclear factor kappaB ligand (RANKL) and osteoprotegerin production by human osteoblastic cells: comparison of the effects of 17-beta oestradiol and raloxifene. Journal of Endocrinology 177 423-433. (Pubitemid 36722298)
8. Ciana P, Di Luccio G, Belcredito S, Pollio G, Vegeto E, Tatangelo L, Tiveron C &Maggi A 2001 Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Molecular Endocrinology 15 1104-1113. (Pubitemid 32618737)
9. Ciana P, Raviscioni M, Mussi P, Vegeto E, Que I, Parker MG, Lowik C & Maggi A 2003 In vivo imaging of transcriptionally active estrogen receptors. Nature Medicine 9 82-86.
10. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M et al. 1999 The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. Journal of the American Medical Association 281 2189-2197.
11. Duan R, Xie W, Burghardt RC & Safe S 2001 Estrogen receptor-mediated activation of the serum response element in MCF-7 cells through MAPK-dependent phosphorylation of Elk-1. Journal of Biological Chemistry 276 11590-11598. (Pubitemid 37385310)
12. Erlandsson MC, Gomori E, TaubeM& Carlsten H 2000 Effects of raloxifene, a selective estrogen receptor modulator, on thymus, T cell reactivity, and inflammation in mice. Cellular Immunology 205 103-109. (Pubitemid 32005726)
13. Erlandsson MC, Jonsson CA, Lindberg MK, Ohlsson C & Carlsten H 2002 Raloxifene- and estradiol-mediated effects on uterus, bone and B lymphocytes in mice. Journal of Endocrinology 175 319-327. (Pubitemid 35414379)
14. Galien R & Garcia T 1997 Estrogen receptor impairs interleukin-6 expression by preventing protein binding on the NF-kappaB site. Nucleic Acids Research 25 2424-2429. (Pubitemid 27303703)
15. Garcia-Perez MA, Del Val R, Noguera I, Hermenegildo C, Pineda B, Martinez-Romero A & Cano A 2006 Estrogen receptor agonists and immune system in ovariectomized mice. International Journal of Immunopathology and Pharmacology 19 807-819. (Pubitemid 46145044)
16. Gize E, Venugopalan M, Glasebrook A & Yang N 1997 Characterization of raloxifene binding and transactivation properties of the estrogen receptor-beta (ERbeta). Journal of Bone and Mineral Research 12 S460.
17. Glasebrook A, Phillips D & Sluka J 1993 Multiple binding sites for the antiestrogen raloxifene (LY156758). Journal of Bone and Mineral Research 8 S268.
18. Green S, Walter P, Greene G, Krust A, Goffin C, Jensen E, Scrace G, Waterfield M & Chambon P 1986 Cloning of the human oestrogen receptor cDNA. Journal of Steroid Biochemistry 24 77-83. (Pubitemid 16047760)
19. Jakacka M, Ito M, Martinson F, Ishikawa T, Lee EJ & Jameson JL 2002 An estrogen receptor (ER)alpha deoxyribonucleic acid-binding domain knock-in mutation provides evidence for nonclassical ER pathway signaling in vivo. Molecular Endocrinology 16 2188-2201. (Pubitemid 35155533)
20. Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S & Gustafsson JA 1996 Cloning of a novel receptor expressed in rat prostate and ovary. PNAS 93 5925-5930. (Pubitemid 26190778)
21. Kushner PJ, Agard DA, Greene GL, Scanlan TS, Shiau AK, Uht RM & Webb P 2000 Estrogen receptor pathways to AP-1. Journal of Steroid Biochemistry and Molecular Biology 74 311-317.
22. Lemmen JG, Arends RJ, van Boxtel AL, van der Saag PT & van der Burg B 2004 Tissue- and time-dependent estrogen receptor activation in estrogen reporter mice. Journal of Molecular Endocrinology 32 689-701. (Pubitemid 38877682)
23. O'Brien JE, Peterson TJ, Tong MH, Lee EJ, Pfaff LE, Hewitt SC, Korach KS, Weiss J & Jameson JL 2006 Estrogen-induced proliferation of uterine epithelial cells is independent of estrogen receptor alpha binding to classical estrogen response elements. Journal of Biological Chemistry 281 26683-26692. (Pubitemid 44401877)
24. Paech K, Webb P, Kuiper GG, Nilsson S, Gustafsson J, Kushner PJ & Scanlan TS 1997 Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 277 1508-1510. (Pubitemid 27449239)
25. Pettersson K, Grandien K, Kuiper GG & Gustafsson JA 1997 Mouse estrogen receptor beta forms estrogen response element-binding heterodimers with estrogen receptor alpha. Molecular Endocrinology 11 1486-1496. (Pubitemid 27366759)
26. Sato M, Kim J, Short LL, Slemenda CW & Bryant HU 1995 Longitudinal and cross-sectional analysis of raloxifene effects on tibiae from ovariectomized aged rats. Journal of Pharmacology and Experimental Therapeutics 272 1252-1259.
27. Stefanick ML 2005 Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. American Journal of Medicine 118 64-73.
28. Syed FA, Modder UI, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL & Khosla S 2005 Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. Journal of Bone and Mineral Research 20 1992-2001. (Pubitemid 41532785)
29. Syed FA, Fraser DG, Spelsberg TC, Rosen CJ, Krust A, Chambon P, Jameson JL & Khosla S 2007 Effects of loss of classical estrogen response element signaling on bone in male mice. Endocrinology 148 1902-1910. (Pubitemid 46457128)
30. Umayahara Y, Kawamori R, Watada H, Imano E, Iwama N, Morishima T, Yamasaki Y, Kajimoto Y & Kamada T 1994 Estrogen regulation of the insulin-like growth factor I gene transcription involves an AP-1 enhancer. Journal of Biological Chemistry 269 16433-16442. (Pubitemid 24209344)
31. Viereck V, GrundkerC, Blaschke S, Niederkleine B, SiggelkowH, Frosch KH, Raddatz D, Emons G & Hofbauer LC 2003 Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts. Journal of Clinical Endocrinology and Metabolism 88 4206-4213. (Pubitemid 37153721)
32. Wang C, Dehghani B, Magrisso IJ, Rick EA, Bonhomme E, Cody DB, Elenich LA, Subramanian S, Murphy SJ, Kelly MJ et al. 2007 GPR30 contributes to estrogen-induced thymic atrophy. Molecular Endocrinology 22 636-648.
33. Windahl SH, Vidal O, Andersson G, Gustafsson JA & Ohlsson C 1999 Increased cortical bone mineral content but unchanged trabecular bone mineral density in female ERbeta(-/-) mice. Journal of Clinical Investigation 104 895-901. (Pubitemid 29536339)
34. Windahl SH, Lagerquist MK, Andersson N, Jochems C, Kallkopf A, Hakansson C, Inzunza J, Gustafsson JA, van der Saag PT, Carlsten H et al. 2007 Identification of target cells for the genomic effects of estrogens in bone. Endocrinology 148 5688-5695. (Pubitemid 350146165)
35. Yang NN, Bryant HU, Hardikar S, Sato M, Galvin RJ, Glasebrook AL & Termine JD 1996a Estrogen and raloxifene stimulate transforming growth factor-beta 3 gene expression in rat bone: a potential mechanism for estrogen- or raloxifene-mediated bone maintenance. Endocrinology 137 2075-2084. (Pubitemid 26133978)
36. Yang NN, Venugopalan M, Hardikar S & Glasebrook A 1996b Identification of an estrogen response element activated by metabolites of 17beta-estradiol and raloxifene. Science 273 1222-1225. (Pubitemid 26293211)
37. Yellayi S, Naaz A, Szewczykowski MA, Sato T, Woods JA, Chang J, Segre M, Allred CD, Helferich WG & Cooke PS 2002 The phytoestrogen genistein induces thymic and immune changes: a human health concern? PNAS 99 7616-7621.